Pauline Lukey
Managing Director, Target to Treatment Consulting Ltd

About me


Summary: reMASTer Therapeutics is a newly formed virtual company that will identify novel synergistic interactions between drugs that can be developed into fixed dose combinations (FDCs) to treat the high unmet need in the rare disease Systemic Mastocytosis (SM).

Who we are: reMASTer consists of 6 pharmaIndustry experts with over 150 years cumulative industry experience that spans across the disciplines required to discover and develop new medicines.

How we work: We work extensively with hand-picked CROs that provide additional services required to achieve our objectives. We have built an extensive ecosystem within which we function, that includes charities, physicians, AI/ML, BioStatistics, IP, MAST cell biology, bioinformatics and business management. We have identified potential partners that are interested in novel Mast Cell therapies and with whom we will work to achieve in vitro PoC, in vivo PoC, clinical PoC and ultimately out-licensing. 

Unmet need: There is high unmet need in SM where patients suffer chronic debilitating symptoms in any and all organs of the body, unexpected anaphylaxis and ultimately organ failure. In fact, in aggressive forms of the disease, their life expectancy is only 2-3 years post-diagnosis.

Innovation: We have built an interactive network-pharmacology model of Mast Cell signalling and function, which we have used to identify key nodes within Mast Cells that are targets for intervention. We have used chemoinformatics to identify a carefully curated TOOLBOX of molecules that will interact with these target nodes. Our intention is to conduct in vitro experiments to confirm our proprietary predictions of synergistic  effects of these molecules. Then we will develop combinations that provide patentable and approvable medicines that will be safer, better tolerated and more effective than monotherapy.

Preliminary work: We have partnered with Domainex (CRO) to conduct some preliminary experiments to provide confidence that our approach is viable. We have successfully cultured Mast Cells and initial in vitro interaction experiments using a limited number of molecules look very promising.

Our advantages: Focussing on a rare disease as PoC has many advantages such as reduced development costs and a greater return on investment compared to non-rare diseases. This puts the developer in a very strong position when negotiating a licensing deal.  In 2015 alone there were more than 700 such licensing deals each worth an average of $350M. In addition, Mast Cells are involved in many other important diseases such as inflammatory (anaphylaxis and asthma), auto-immune (rheumatoid arthritis) and metabolic (type II diabetes) diseases.  These additional, potential indications add value to effective FDCs invented and thus widen the scope of our exit strategy.

What we need: We are seeking seed funding (£500K) to achieve initial in vitro PoC.

Matchmaking Information

Processing. Please wait.